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Abstract
Background: Diabetes has a high burden of illness both in life years lost and in disability through
related co-morbidities. Accurate assessment of the non-mortality burden requires appropriate
health-related quality of life and summary utility measures of which there are several contenders.
The study aimed to measure the impact of diabetes on various health-related quality of life domains,
and compare several summary utility measures.
Methods: In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron
MR Controlled Evaluation) study, 978 Australian patients with Type 2 diabetes completed two
health-related quality of life questionnaires at baseline: the EQ-5D and the SF-36v2, from which
nine summary utility measures were calculated, and compared. The algorithms were grouped into
four classes: (i) based on the EQ-5D; (ii) using fewer items than those in the SF-12 (iii) using the
items in the SF-12; and (iv) using all items of the SF-36.
Results: Overall health-related quality of life of the subjects was good (mean utility ranged from
0.68 (±0.08) to 0.85(±0.14) over the nine utility measures) and comparable to patients without
diabetes.  Summary indices were well correlated with each other (r = 0.76 to 0.99), and showed
lower health-related quality of life in patients with major diabetes-related events such as stroke or
myocardial infarction. Despite the smaller number of items used in the scoring of the EQ-5D, it
generally performed at least as well as SF-36 based methods. However, all utility measures had
some limitation such as limited range or ceiling effects.
Conclusion: The summary utility measures showed good agreement, and showed good
discrimination between major and minor health state changes. However, EQ-5D based measures
performed as well and are generally simpler to use.
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Many randomized control trials of therapies for Type 2
Diabetes now routinely include a generic health-related
quality of life instrument administered to patients at base-
line and during follow-up. The two most commonly used
generic instruments are the EQ-5D [1] and the Short-Form
36 (SF-36) [2]. The EQ-5D has been used in the UKPDS
[3], the Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study [4], and most recently the
ADVANCE (Action in Diabetes and Vascular Disease: Pre-
terax and Diamicron MR Controlled Evaluation) study
[5]. The SF-36 has been used in the Lipids in Diabetes
Study (LDS) [6], ADOPT [7] and on a sub-set of patients
in both FIELD and ADVANCE.
While the generic instruments provide information that
enables comparison of the health status of the study par-
ticipants with other populations (e.g. comparisons of the
SF-36 domain scores with norms for the general popula-
tion), they are primarily used in the valuation of out-
comes in economic evaluation. This typically involves use
of predefined algorithms to convert item survey responses
into a utility scale where 1.0 implies the patient is in per-
fect health and 0.0 is a health state equivalent to death.
This is the most commonly used approach to estimate
quality adjusted life years (QALYs) and provides a com-
posite measure that aims to incorporate survival and
health-related quality of life into a single index. QALYs are
a particularly important outcome measure in the evalua-
tion of therapies for a disease such as diabetes where com-
plications, such as amputation, can have a considerable
impact on overall health-related quality of life.
While many trials in diabetes now routinely include one
or more generic health-related quality of life instrument
there is no consensus as to either which instrument
should be used, or which algorithm should be applied, to
convert patient responses into utilities. In the case of the
EQ-5D, traditionally the most commonly used algorithm
was derived from a study involving individuals from the
UK population [8]. However, recently a comparable study
using a random sample of the United States population
has becoming available [9], thereby providing researchers
with an alternative set of utility for the same health states.
There are at least seven published algorithms [10,12-17]
for converting either item responses, or summary scores,
from the SF-36 into preference based utility measures.
Most of these algorithms are based on subsets of ques-
tions from the SF-36. For example, the SF-6D uses only 11
items of the 36 items, and other algorithms, such as those
developed by Lundberg and colleagues [10], are based on
the shorter generic instrument, the SF-12 (which is based
on 12 of the 36 questions of the SF-36). Clearly research-
ers who intend to measure the health related quality of life
of people with diabetes face an array of choices regarding
which generic instrument to use, and then which algo-
rithm to employ.
The purpose of this study is to compare summary statistics
of the estimated utility values produced by different algo-
rithms for common complications of diabetes. In particu-
lar we are interested to see if there are systematic
differences in both the absolute mean utility values and
the deviations associated with each type of diabetes-
related complication.
Methods
Study population
All patients included in this study were participating in
the ADVANCE (Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation)
study. ADVANCE is a randomised 2 × 2 factorial trial in
11,140 normotensive patients with Type 2 diabetes com-
paring (i) intensive, gliclazide-based therapy or regular,
guideline-based glucose control therapy in patients with
Type 2 diabetes, and (ii) intensive blood pressure lower-
ing based on a perindopril-indapamide combination or
matching placebo [11]. The intensive gliclazide-based reg-
imen aims to reduce haemoglobin A1C to 6.5% or lower
(compared with haemoglobin A1C targets of 7–8% sug-
gested by most regional guidelines) [5].
Quality of life instruments
Two health-related quality of life questionnaires are being
used in the ADVANCE trial: the EQ-5D (EuroQol 5-
Dimensions) and the SF-36v2 (Short Form 36 version 2).
The EQ-5D has five questions – on mobility, personal
care, usual activities, pain/discomfort, and anxiety/
depression – each encompassing the range of values 1 (=
no problems), 2 (= some problems), 3 (= severe prob-
lems).
The SF-36v2 is a multipurpose short-form survey with 36
questions that measure eight health attributes using
multi-item scales containing 2 to 10 items each. These
attributes are: (1) physical functioning, (2) role limita-
tions due to physical health problems, (3) bodily pain,
(4) general health, (5) vitality (energy/fatigue), (6) social
functioning, (7) role limitations due to emotional prob-
lems, and (8) mental health (psychological distress and
psychological well-being). The SF-12 and SF-6D are
health-related quality of life instruments that use a subset
of these items.
The EQ-5D was administered to all patients in the
ADVANCE trial, from the 20 participating countries. The
SF-36v2 questionnaire was administered to the subgroup
of Australian patients only. Both questionnaires were
administered at baseline and 2 years after randomizationPage 2 of 11
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EQ-5D with the SF-36 we have restricted the analysis to
the Australian patients.
Utility measures
We undertook a literature search to identify studies that
reported algorithms to convert generic health-related
quality of life instruments into utility values which could
potentially be used in valuing outcomes in economic eval-
uations. We identified seven studies [10,12-17] that used
items from the SF-36, and two [8,9] using the EQ-5D, that
were published prior to December 2005. The main fea-
tures of these algorithms (which are ranked by the
number of items they require) are summarized in Table 1.
The algorithms can be grouped into four classes: (i) those
based on the EQ-5D [8,9]; (ii) those algorithms using
fewer items than the SF-12 (i.e. SF-6D) [12,13] (iii) those
that use the SF-12 [10,14-16]; (iv) those that use all items
of the SF-36 [17]. All studies except Lawrence [14] and
Franks [15,16] involve utilities derived from studies
involving primary direct assessment of utilities e.g., using
standard gamble or time trade-off methods.
Statistical analysis
We report summary statistics for patients with a history of
any of seven diabetes-related complications: stroke or
transient ischemic attack (TIA), peripheral revasculariza-
tion and/or amputation, hospital admission for unstable
angina, myocardial infarction, coronary artery bypass
graft, and currently treated for hypertension. This history
was reported on the baseline form. The mean (sd) utility
for those with the complication, without the complica-
tion, and without any of the complications, was calcu-
lated for all nine algorithms. Confidence intervals were
calculated for differences in the mean level of utility of
those experiencing each type of complication with those
not experiencing that complication in the Australian
ADVANCE population, and displayed graphically. To
compare how the mean difference in utility varied
between algorithms we ranked the severity (using mean
deficit in utility values) of the seven complications of dia-
betes for each utility measure, then used Spearman's rank
correlation coefficient to assess the degree of consistency
in ranking. We also graphed the average difference in
mean utility for these complications by the four classes of
algorithm.
To estimate the within-person variability, we used the
measures in the subgroup of patients who had had no
major adverse event between the baseline and two-year
qol measurements. This was used to define a signal-to-
noise ratio as the difference in mean utility between those
who had a major event and those who did not, divided by
the standard deviation of the utility measure in those who
did not have a major event. Furthermore, linear regression
models were used to assess the statistical significance of
the presence of a major event on change in 2-year utility
score, adjusted for baseline score.
Results
Subjects
Characteristics of the ADVANCE study population have
been published [11], and included a total of 978 Austral-
ian patients randomized. This Australian cohort was 71%
male, had a mean age of 67 (range = 55–86) years at reg-
istration, and a baseline mean hemoglobin A1c (HbA1c)
of 7.2 (sd = 1.2). The average duration of diabetes was 7.2
years (sd = 6.1 years). The two health-related quality of life
measurement instruments, the SF-36v2 and the EQ-5D,
were administered at baseline to all 978 patients, with 975
responses (99.6%) to the EQ-5D, and 978 responses
(100%) to the SF-36v2.
Utility scores
Table 1 includes information on the range of utility values
in our study population. The Weighted Health Index
(WHI) utility measure (calculated from the EQ-5D) was -
0.18 to 1.0 when calculated using the Dolan algorithm,
and 0.20 to 1 for the Shaw algorithm. The range of the
Brazier index, based on the SF-6D, was 0.35 to 1.0, and
the Lundberg 0.43 to 0.98.
Table 2 shows the mean (sd) utility scores for each of the
utility measures broken down by presence or absence of
the seven individual diabetes-related complications at
baseline. It also includes these same measurements for the
subset of patients (21.5%) who had no history of any of
these complications at baseline. There was moderate vari-
ation in the average utility values. For example, for the
10.5% of patients who had previously experienced a
stroke or TIA, the mean utility ranged from approximately
0.650 (for Fryback and Franks SF-12-MEPS algorithms),
up to 0.783 for the Shaw (EQ-5D) algorithm. When
examining the difference in utility values between those
who had a history of the nominated medical conditions,
and those who didn't, the instruments based on either the
EQ-5D (Dolan and Shaw), or based on instruments that
mapped utility values from the EQ-5D (i.e. Franks MEPS,
Lawrence MEPS, Franks SF-12) appear to have greater dif-
ferences than the algorithms designed specifically for the
SF-36 (i.e. Lundberg, SF-6D and Fryback). For example,
the difference between the utility value of a past stroke/
TIA, for those instruments based on EQ-5D or mapped
values from the EQ-5D, ranged between a decrement of
0.104 (Dolan) to 0.073 (Shaw), while the decrement for
the others ranged from 0.051 for Brazier (SF-36) to 0.034
for Fryback. Diagramatically, this information is pre-
sented in Figure 1, where, for each algorithm, the mean
differences (and 95% CI) for all of the complications arePage 3 of 11
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Table 1: Algorithms to convert item responses from generic health-related quality of life instruments into utility measures
Study (denoted by 
primary author and 
instrument)
Dolan EQ-5D Shaw EQ-5D Brazier SF-6D 
(SF-12)
Brazier SF-6D 
(SF-36)
Lundberg SF-
12
Lawrence SF-
12 (MEPS)
Franks SF-12 
(MEPS)
Franks SF-12 Fryback SF-36
Type of Algorithm EQ-5D based algorithm SF-6D based algorithm SF-12 based algorithm SF-36 based 
algorithm
QoL Questionnaire EQ-5D EQ-5D SF-12 SF-36 SF-12 SF-12 SF-12 SF-12 SF-36
Number items used 5 5 7 11 (of 36) 12 (of 36) 12 12 12 36
Methods for valuing 
utility
Time Trade Off Time Trade Off Standard Gamble Standard Gamble Time Trade Off Mapping to the 
UK based EQ-
5D tariffs
Mapping to the 
UK based EQ-
5D tariffs
Mapping to the 
UK based EQ-
5D tariffs
Quality well being 
index
Reported range in 
the ADVANCE trial 
patients
-0.18 to 1 0.20 to 1 0.41 to 1 0.35 to 1 0.47 to 0.98 0.20 to 1.01 0.046 to 0.975 -0.07 to 0.94 0.509 to 0.836
Health states 
sampled
243 243 249 249 NA NA NA NA NA
Population General 
population
General 
population
General population General 
population
General 
population
General 
population
General 
population
Low income, 
minority 
population
General population
Country where 
developed
UK USA UK UK Sweden USA USA USA USA
Description of 
process
3,667 individuals 
rating 12 health 
states from the 
possible 243 
states.
4,048 individuals 
rating 13 from 
the possible 243 
states.
611 individuals 
rating 6 health 
states from 6-
dimensional health 
state classification 
(3518 
observations)
611 individuals 
rating 6 health 
states from 6-
dimensional 
health state 
classification 
(3518 
observations)
Postal 
questionnaire 
5,400 individuals 
using SF12 plus 
TTO question. 
Regression used 
to derive 
utilities.
14,580 
respondents 
who completed 
the Medical 
Expenditure 
Panel survey 
2000.
15,000 
respondents 
who completed 
the Medical 
Expenditure 
Panel survey 
2000.
240 respondents 
attending a 
community 
health centre in 
New York
1,356 respondents 
who participated in 
the Beaver Dam 
Health study
Health and Quality of Life Outcomes 2007, 5:21 http://www.hqlo.com/content/5/1/21shown as deficits in utility value, with zero indicating no
difference.
Table 3 shows the results of the rank correlations of the
utility differences derived from values reported in Table 2.
Overall there is a good consistency in the ranking for the
seven complications: the Spearman's rank correlation
coefficient ranges from 0.991 (between Shaw and Dolan)
to 0.757 (between Dolan and Franks). The utility differ-
ences were then allocated to the four algorithm classes
and averaged for each class. Figure 2 graphically repre-
sents the variability amongst the four algorithm classes.
The two health-related quality of life instruments (SF-36
and EQ-5D) were administered to all patients again at
approximately two year after baseline. During this time,
details of any serious adverse events (SAEs) experienced
by the patients were also collected and then used in con-
junction with the 2-year qol information to examine
changes in health status since baseline. In the ADVANCE
study, serious adverse events are defined as events that:
(1) result in death, (2) are life threatening in the opinion
of the responsible investigator,(3) require inpatient hos-
pitalisation or prolongation of existing hospitalization,
(4) result in persistent or significant disability or incapac-
ity, (5) result in congenital anomaly or birth defect
(unlikely since participants must be aged 55 years or over
at entry to study), and (6) are important medical events in
the opinion of the responsible investigator. The presence
or absence of an SAE was then used in conjunction with
the difference in utility measure between baseline and
two-year values to calculate regression coefficients and
signal/noise ratios (Table 4). Most algorithms showed
similar signal-to-noise ratios, indicating that they have
similar sensitivity to clinically relevant changes in health
status.
Discussion
Health technology assessments increasingly rely on
generic health-related quality of life instruments, and
published algorithms, for deriving utilities in order to
quantify outcome of interventions to prevent or treat dia-
betes and its complications. This study provides evidence
on the degree of variation in utility scores for common
diabetes-related complications when they are derived
using different algorithms for patients enrolled in the
ADVANCE trial.
Our results demonstrate that there is a moderate variation
among algorithms in the average utility score for many
complications, and in the degree to which those with
complications differ from the rest of the ADVANCE
patients. While there is a high level of agreement among
the instruments in their ranking of the severity of compli-
cations, it would appear that those algorithms based on
the EQ-5D produce greater mean differences for macro
vascular complications such as stroke, as might be clini-
cally expected. For example, mean difference in utility for
patients with a stroke or TIA compared with the rest of the
ADVANCE patients is around 0.1 for the Dolan (EQ-5D)
algorithm, but only 0.05 for the Brazier SF-6D (SF-36)
algorithm (see Figure 1), but both algorithms rank it as
having the greatest impact on the mean difference in util-
ity.
The use of alternative utilities for the same health states
when evaluating interventions for diabetes has important
implications for cost-effectiveness analysis, as the degree
to which a therapy may be cost-effective may depend on
which method is used to derive utilities [18]. In these cir-
cumstances, what criteria could be used to choose an
appropriate method for assessing health-related quality of
life of patients with diabetes? One obvious approach
would be to compare the utilities derived from these
generic instruments with those elicited directly from
patients, or the community, using such methods as time-
trade-off or standard gamble techniques. Unfortunately,
while directly elicited utility values have been reported for
a limited range of complications (e.g. amputation [18]),
currently there is insufficient information to undertake a
systematic comparison.
Secondly, the utility algorithm should provide sufficient
sensitivity. This includes both being responsive to major
changes in health state (see criterion 1 above), and also
demonstrating minimal day-to-day fluctuation when no
major changes have occurred. That is, a good "signal-to-
noise" ratio. Those instruments based on direct valuation
of health states (i.e. EQ-5D and SF-36) tend to have lower
signal to noise ratios (indicating greater variation in the
utility measures) than those using some form of mapping,
however this is due to differences in methods of deriva-
tion. In particular, the latter is generally based on predic-
tions of mean utilities derived from regression equations
that tend to reduce the degree of variation across health
states. In regard to the instruments based on direct valua-
tion, the EQ-5D generally seemed to perform as well as
the SF-36 based methods. This is somewhat surprising
given the smaller number of items assessed and used in
the scoring of the EQ-5D.
A third criterion for choosing a utility instrument is the
generation of an appropriate range for the utility values.
In this regard, the Brazier algorithm, which is now the
standard summary score for the SF-36, has a much nar-
rower range as it cannot achieve scores lower than 0.296.
This limits the degree to which it can characterize the util-
ity associated with extremely poor health states, such as
disabling stroke. The Lundberg score was highly corre-
lated with the Brazier score and showed similar problemsPage 5 of 11
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Table 2: Mean (sd) utility measures by presence of diabetes-related complications at baseline
% of study 
population
 Utilities 
Dolan (EQ-5D) Shaw (EQ-5D) Brazier SF-6D 
(SF12)
Brazier 
SF-6D 
(SF36)
Lundberg 
(SF-12)
Lawrence 
(SF12-
MEPS)
Franks 
(SF12-
MEPS)
Franks (SF12) Fryback 
(SF36v1)
All patients 100% (n = 975) 0.801 (0.206) 0.848 (0.144) 0.780 (0.131) .746 (0.138) 0.801 (0.103) 0.728 (0.182) .725 (0.189) 0.744 (0.186) 0.678 (0.079)
MEDICAL 
CONDITION
Stroke and/or TIA Y 10.5% .708 (0.259) .783 (0.174) .744 (0.141) .700 (0.142) .762 (0.112) .659 (0.192) .650 (0.207) .666 (0.211) .648 (0.082)
N .812 (0.196) .856 (0.138) .784 (0.129) .751 (0.136) .804 (0.102) .736 (0.179) .734 (0.185) .754 (0.181) .682 (0.078)
Peripheral 
Revascularization and/or 
Amputation
Y 5.4% .722 (0.236) .793 (0.159) .730 (0.149) .698 (0.146) .751 (0.116) .646 (0.207) .633 (0.232) .643 (0.250) .638 (0.078)
N .805 (0.204) .851 (0.143) .782 (0.129) .749 (0.137) .803 (0.102) .733 (0.179) .730 (0.185) .750 (0.180) .681 (0.079)
Hospital admin for unstable 
Angina
Y 12.6% .741 (0.242) .805 (0.165) .739 (0.148) .703 (0.146) .768 (0.116) .661 (0.198) .654 (0.214) .678 (0.222) .655 (0.083)
N .809 (0.199) .854 (0.140) .785 (0.127) .752 (0.137) .804 (0.101) .737 (0.177) .735 (0.184) .754 (0.179) .682 (0.078)
Myocardial Infarction Y 18.8% .767 (0.223) .826 (0.152) .764 (0.136) .732 (0.138) .778 (0.105) .695 (0.182) .692 (0.195) .715 (0.200) .665 (0.078)
N .808 (0.202) .853 (0.142) .783 (0.130) .749 (0.138) .805 (0.103) .736 (0.181) .732 (0.188) .751 (0.182) .682 (0.079)
Coronary artery bypass 
graft
Y 18.6% .788 (0.211) .839 (0.146) .769 (0.136) .736 (0.140) .788 (0.107) .710 (0.185) .706 (0.198) .727 (0.205) .673 (0.082)
N .804 (0.205) .850 (0.144) .782 (0.130) .748 (0.137) .803 (0.102) .732 (0.181) .729 (0.187) .748 (0.182) .680 (0.079)
Currently treated 
Hypertension
Y 64.7% .789 (0.209) .839 (0.145) .769 (0.132) .735 (0.137) .794 (0.102) .710 (0.181) .707 (0.190) .728 (0.189) .670 (0.078)
N .823 (0.199) .865 (0.141) .798 (0.127) .767 (0.138) .814 (0.103) .763 (0.178) .759 (0.184) .775 (0.177) .694 (0.080)
Diabetic Eye Disease incl. 
Blindness in either eye
Y 7.6% .801 (0.177) .848 (0.126) .769 (0.131) .732 (0.142) .779 (0.105) .697 (0.190) .690 (0.202) .710 (0.199) .669 (0.073)
N .801 (0.208) .848 (0.145) .780 (0.131) .747 (0.138) .801 (0.103) .731 (0.181) .728 (0.188) .747 (0.185) .679 (0.080)
Patients without above 
conditions at baseline
21.5% .843 (0.186) .877 (0.135) .802 (0.125) .771 (0.137) .824 (0.098) .778 (0.174) .774 (0.177) .788 (0.165) .701 (0.079)
Duration of Diabetes >= 5 yrs 47.3% .808 (0.208) .853 (0.146) .782 (0.133) .750 (0.141) .796 (0.105) .726 (0.185) .722 (0.193) .740 (0.191) .678 (0.082)
6+ yrs 52.7% .793 (0.205) .843 (0.142) .777 (0.129) .743 (0.135) .802 (0.102) .730 (0.179) .727 (0.186) .748 (0.182) .679 (0.077)
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Mean deficit (and 95% CIs) in utility value at study baseline for patients with selected medical conditionFigure 1
Mean deficit (and 95% CIs) in utility value at study baseline for patients with selected medical condition.
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rithms generally produced smaller differences for those
with and without particular complications, than algo-
rithms based on EQ-5D utility values. This has also been
observed in other disease areas such as patients with liver
transplantation [19] in which patients 12 months after
transplant had a significant improvement in utilities
derived from the EQ-5D, but not from the SF-6D. A simi-
lar pattern has been found for patients visiting a rheuma-
tology clinic [20].
A final criterion is the simplicity or ease of administration
of the instrument. The collection of health-related quality
of life information is often subject to cost or time con-
straints, as the contact time with a patient in trials is lim-
ited. Hence the administration of the health-related
quality of life instrument has an opportunity cost in terms
of reducing the time available to collect other informa-
tion. The SF-36 is usually administered as a self-com-
pleted questionnaire which contains 36 items covering
different aspects of health-related quality of life, and
administered when patients attend clinics. While the
developers of the SF-36 state that it can usually be com-
pleted in 5 to 10 minutes[21], at least one study has indi-
cated that it may take, on average, 15 minutes to
administer in some elderly populations [22]. The EQ-5D
is a shorter five item questionnaire which has three
response levels to each item and hence its administration
time is likely to be well below five minutes. Besides the
cost of administration, the use of the EQ-5D may have
other advantages as it has been shown to have a higher
response rate than those based on the SF-36 and, given the
small number of items, there is a greater chance of full-
completion which minimizes the problem of missing data
[23]. Unless the researcher is interested in deriving
domain scores for the SF-36, another option would be to
ask a sub-set of questions that match the existing instru-
ments. In this regard, the SF-12 would appear to be a good
choice, as five of the seven algorithms were based on SF-
12.
Since researchers must choose a utility algorithm in addi-
tion to choosing a quality of life instrument, the differ-
ences in the utilities for the EQ-5D derived using the
algorithms developed by Shaw for a US population and
original tariffs that were derived in the United Kingdom
are of note. For example, the Dolan algorithm indicated
patients with no complications had a utility around 0.8
(similar to previous studies that used this algorithm
[3,24]), while the Shaw algorithm utility gave values 0.05
higher for the same group of patients. While this may
reflect differences in health related quality of life between
these populations, it is not obvious which should be used,
especially in countries where valuation exercises to derive
tariff values for EQ-5D states have not been undertaken.
Given the increasing internationalization of clinical trials
it is important to address this issue in future work.
Finally it is important to consider the limitations of the
study. First, patients were restricted to Australian patients
with diabetes who were eligible and willing to participate
in a clinical trial, and hence it may not be a representative
sample. However, we were not trying to estimate popula-
tion values but rather to analyze the relationship between
health states and utility, and there appeared to be suffi-
cient diversity of the sample for this. Second, and more
crucial, was the limited data on the nature and timing of
the prior and intercurrent events. For example, though we
have treated stroke as a single state, its effects are diverse
ranging from full recovery to severe disability. Third, we
ignore multiple morbidities within individual patients,
but as these were relatively rare it is unlikely to make
much difference to the comparisons. Fourth, while we
had patients complete the full SF-36, some of the utility
scorings only used a subset of questions. Finally, our esti-
mate of test-retest stability is based on patients with no
event re-measured after 2 years, and it is likely that the var-
iability represents measurement error plus some real,
though minor, changes. However, this is common across
all the utility measures and hence should not greatly influ-
ence the relative signal-to-noise ratio.
Table 3: Correlations between utility measures on ranking of severity of seven complications of diabetes
UTILITY MEASURES Dolan Shaw Brazier SF6D 
(SF12)
Brazier 
SF6D (SF36)
Lundberg Lawrence Franks MEPS Franks Fryback
Dolan 1.000
Shaw 0.991* 1.000
BrazierSF6D (SF12) 0.837 0.862 1.000
BrazierSF6D (SF36) 0.842 0.878 0.943 1.000
Lundberg 0.852 0.860 0.868 0.932 1.000
Lawrence 0.917 0.925 0.953 0.971 0.932 1.000
Franks_MEPS 0.818 0.853 0.944 0.972 0.962 0.943 1.000
Franks 0.757 0.791 0.835 0.935 0.972 0.878 0.963 1.000
Fryback 0.918 0.926 0.963 0.923 0.933 0.962 0.953 0.871 1.000
* Spearman's rank correlation coefficientPage 8 of 11
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Difference in mean utility for selected complications (grouped by 4 classes of algorithms).
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Health and Quality of Life Outcomes 2007, 5:21 http://www.hqlo.com/content/5/1/21Conclusion
In conclusion, there was considerable variation across the
different algorithms for translating responses to the EQ-
5D and SF-36 into utilities. Algorithms based on survey
instruments covering more comprehensive aspects of
health-related quality of life did not appear to measure
greater variations in utility than those based on simpler
instruments such as EQ-5D. Taking this into account, the
lower administration time of the EQ-5D suggests that it
has real advantages over the SF-36 when collecting health-
related quality of life information as part of a clinical trial.
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